Cystic fibrosis-related diabetes and lung disease: an update

Bernadette J Prentice; Adam Jaffe; Shihab Hameed; Charles F Verge; Shafagh Waters; John Widger

doi:10.1183/16000617.0293-2020

Cystic fibrosis-related diabetes and lung disease: an update

Eur Respir Rev. 2021 Feb 16;30(159):200293. doi: 10.1183/16000617.0293-2020. Print 2021 Mar 31.

Authors

Bernadette J Prentice^{1

2}, Adam Jaffe^{3

2}, Shihab Hameed^{2

4

5}, Charles F Verge^{2

5}, Shafagh Waters^{2

6}, John Widger^{3

2}

Affiliations

¹ Dept of Respiratory Medicine, Sydney Children's Hospital, Randwick, Australia Bernadette.prentice@health.nsw.gov.au.
² School of Women's and Children's Health, University of New South Wales, Sydney, Randwick, Australia.
³ Dept of Respiratory Medicine, Sydney Children's Hospital, Randwick, Australia.
⁴ Faculty of Medicine, University of Sydney, Sydney, Australia.
⁵ Dept of Endocrinology, Sydney Children's Hospital, Randwick, Australia.
⁶ MiCF Research Centre, Sydney, Australia.

Abstract

The development of cystic fibrosis-related diabetes (CFRD) often leads to poorer outcomes in patients with cystic fibrosis including increases in pulmonary exacerbations, poorer lung function and early mortality. This review highlights the many factors contributing to the clinical decline seen in patients diagnosed with CFRD, highlighting the important role of nutrition, the direct effect of hyperglycaemia on the lungs, the immunomodulatory effects of high glucose levels and the potential role of genetic modifiers in CFRD.

Publication types

Review

MeSH terms

Cystic Fibrosis* / complications
Cystic Fibrosis* / diagnosis
Cystic Fibrosis* / epidemiology
Diabetes Mellitus* / diagnosis
Diabetes Mellitus* / epidemiology
Humans
Lung